**SUPPLEMENTARY** **FIGURE 1. Primary CD138+-myeloma cells in bone marrow aspirates express αvβ3/αvβ5 integrins­ and IGF1R.** Bone marrow aspirates from 12 individual patients were incubated on Sdc1 antibody to capture CD138+ myeloma cells and exclude other cell types present in the aspirates. Captured cells were fixed and stained for αvβ3 (LM609), αvβ5 (P1F6), or IGF1R (JBW902). Stained cells were counted and expressed as a percentage of total captured cells. Data points represent the mean of a minimum of four replicates for each patient.

**SUPPLEMENTARY FIGURE 2. SSTN inhibition of IGF1R in myeloma inhibits adhesion-independent cell survival.** **A.** CAG cells are plated for 2 hr on VN or FN in the presence or absence of 10 μg/mL VLA-4 (P1H4) or 30 μg/mL αvβ5 (P1F6) integrin blocking antibodies; **B.** CAG myeloma cells grown for 72 hr in the presence of 10 μg/mL VLA-4 (P1H4) or 30 μg/mL αvβ5 (P1F6) integrin blocking antibodies, 10 μM AG538, or 30 μM SSTNIGF1R­ are quantified and graphed relative to no treatment (set to 1.0). Error bars = SEM.